What is the history of Elastofibroma Dorsi?

Elastofibroma dorsi is a rare, benign soft-tissue pseudotumor first described in the medical literature in 1959 by Finnish pathologist Olavi Järvi and researcher E. Saxén. While initially considered a rare curiosity, modern imaging has revealed that elastofibroma dorsi is significantly more common than previously believed, particularly in elderly populations, though it remains frequently underdiagnosed due to its often asymptomatic nature.

Who first identified Elastofibroma dorsi?

The condition was formally characterized in 1959 when Järvi and Saxén identified the unique histological features of elastofibroma dorsi, noting the presence of abnormal elastic fibers within a fibrous stroma. They recognized that these growths typically occurred in the subscapular region, situated between the thoracic wall and the scapula, a location that remains the diagnostic hallmark of the condition today.

How has our understanding of the condition evolved?

Historically, elastofibroma dorsi was shrouded in mystery, with early researchers debating whether it represented a true neoplasm or a reactive process. Through the late 20th century, the medical consensus shifted toward viewing it as a reactive, fibroelastic proliferative process rather than a malignant tumor. Advancements in imaging, specifically the widespread use of MRI and CT scans, have allowed clinicians to identify the characteristic location of elastofibroma dorsi without the need for invasive biopsies in many cases.

What are the major historical milestones in management?

The management of elastofibroma dorsi has transitioned from an era of exploratory surgery to a conservative, observation-based approach:

• 1960s-1980s: Surgical excision was the primary standard, often performed to rule out malignancy.


• 1990s-2000s: The introduction of high-resolution MRI allowed for non-invasive diagnosis, confirming the benign nature of elastofibroma dorsi.


• Present day: Conservative management is now preferred for asymptomatic patients, with surgery reserved only for those experiencing significant pain or physical limitation.

How has patient awareness changed?

Historically, patients were often alarmed by the presence of a palpable mass, leading to unnecessary anxiety and aggressive interventions. Today, platforms like DiseaseMaps.org, where 7 members currently share their experiences, provide a space for patients to find validation and learn that elastofibroma dorsi is a benign condition that rarely requires urgent intervention.

Next steps

• Consult an orthopedic oncologist or a radiologist if you have discovered a new subscapular mass.


• Request an MRI to definitively distinguish elastofibroma dorsi from other soft-tissue masses.


• Join patient communities to discuss long-term management strategies with others who have been diagnosed.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: Portal for rare diseases and orphan drugs


• PubMed: Historical review of subscapular elastofibroma


• OMIM (Online Mendelian Inheritance in Man)